DIABETES MELLITUS and Prednisone

PatientsVille

DIABETES MELLITUS Symptoms and Causes

Diabetes is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose comes from the foods you eat. Insulin is a hormone that helps the glucose get into your cells to give them energy. With type 1 diabetes, your body does not make insulin. With type 2 diabetes, the more common type, your body does not make or use insulin well. Without enough insulin, the glucose stays in your blood. You can also have prediabetes. This means that your blood sugar is higher than normal but not high enough to be called diabetes. Having prediabetes puts you at a higher risk of getting type 2 diabetes.

Over time, having too much glucose in your blood can cause serious problems. It can damage your eyes, kidneys, and nerves. Diabetes can also cause heart disease, stroke and even the need to remove a limb. Pregnant women can also get diabetes, called gestational diabetes.

Blood tests can show if you have diabetes. One type of test, the A1C, can also check on how you are managing your diabetes. Exercise, weight control and sticking to your meal plan can help control your diabetes. You should also monitor your blood glucose level and take medicine if prescribed.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Check out the latest treatments for DIABETES MELLITUS

➢ DIABETES MELLITUS treatment research studies

➢ Prednisone clinical trials, surveys and public health registries

Find Drug Side Effect reports

Prednisone Side Effects

Dyspnoea (309)

Pyrexia (283)

Nausea (273)

Pain (263)

Diarrhoea (255)

Arthralgia (247)

Fatigue (246)

Headache (234)

Pneumonia (231)

Pain In Extremity (210)

Asthenia (210)

Vomiting (205)

Dizziness (201)

Oedema Peripheral (198)

Weight Increased (187)

Weight Decreased (175)

Abdominal Pain (172)

Back Pain (169)

Condition Aggravated (161)

Anaemia (156)

Crohn's Disease (113)

Sepsis (110)

Osteonecrosis (105)

Dehydration (104)

Malaise (104)

Fall (101)

Insomnia (100)

Death (100)

Injection Site Pain (100)

Chest Pain (97)

Cough (96)

Confusional State (96)

Diabetes Mellitus (91)

Rash (89)

Blood Glucose Increased (88)

Anxiety (88)

Pulmonary Embolism (88)

Rheumatoid Arthritis (85)

Pruritus (83)

Hypertension (82)

Hypotension (80)

Depression (80)

Febrile Neutropenia (79)

Erythema (78)

Renal Failure (77)

Neutropenia (74)

Deep Vein Thrombosis (73)

Renal Failure Acute (71)

Hyperglycaemia (69)

Muscular Weakness (69)

➢ More

Common Meds

Abilify (10132)

Adderall (1304)

Amlodipine (6664)

Amoxicillin (4387)

Benadryl (1568)

Celebrex (12876 )

Celexa (1342)

Cialis (2975)

Cipro (8580)

Citalopram (7792)

Crestor (18839)

Cymbalta (14373)

Doxycycline (1757)

Effexor (7289)

Flexeril (435)

Flomax (2177)

Fluoxetine (4261)

Gabapentin (4593)

Hydrocodone (2469)

Ibuprofen (8222)

Lantus (10968)

Lexapro (3499)

Lipitor (17769)

Lisinopril (8919)

Lyrica (27148)

Medrol (650)

Mirena (41254)

Mobic (957)

Morphine (5356)

Naproxen (538)

Neurontin (6501)

Oxycodone (4438)

Pradaxa (13372)

Prednisone (5926)

Prilosec (2631)

Prozac (1954)

Seroquel (27216)

Simvastatin (8348)

Synthroid (4452)

Tamiflu (5585)

Topamax (3748)

Tramadol (5054)

Trazodone (1458)

Viagra (5394)

Vicodin (1153)

Wellbutrin (6324)

Xanax (2847)

Zocor (5718)

Zoloft(6792)

Zyrtec(1669)

Recent Reviews

&gt;:o :'(

3 weeks after i had been given 120m of predisone in a 24 hour period,i started getting dizzy spells severe enough that initially i blacked out while driving,needless to say i havent been driving my car,but i still am experiencing very bad dizzy spell

66 year old male. Good to excellent health. Non smoker, non drinker. Slowly deteriorated till all joints were swollen and eventually I became 99% immobile. Diagnosis? Spotless, Rocky Mountain Spotted Fever. (erlickiosis chaffnesis) Hospitalized, inf

Female patient 39 taking prednisone for asthma. Prednisone 20 mg 4 days on and then one day off/one day onfor8 days. Menstrual type bleeding although not during menstrual period. Severe pelvic cramps and urgency of urination. Swol

I am asthmatic (since I was very little) 36yrs old, took 40mg Prednisone for 8 days - two days later I ovulated and then I started bleeding uncontrollably. Gynae said ovaries failed as blood work tested very low and put me on Duphaston to aid drying

I have taken Prednisone for severe asthma on many occassions (including IV in hospital for 7 days) and suffered severe abdominal pain. Three years ago a gastroscopy revealed I had Duodenal ulcers and Gastritis, most likely caused from the Prednisilo

I received an injection of zostavax in August 2005 and approx 3 months later I was diagnosed with TYPE 1 DIABETES. No one in my entire family history has ever had diabetes. I was and still am 185 lbs.

I take it when i get poison oak or ivy really bad and it takes it away in like 3 days if im fully broken out and i am highly allergic poison ivy, oak and all of that other stuff like that and this stuff helps me tremendously :-D

I take prednione 10mg : 3 tablets once daily for 3 days,then 2 tablets once daily for 3 days,then 1 tabletonce daily for 3 days, then hallf tablets for 4 days. Prednisone give more energy because I have Refractory Anemia with Ringed oblast

I was on a higher dosage - 40mg for 8 days and a few days after I stopped, I started with a 'breakthrough' bleed. Had to have blood tests taken and it showed ovarian failure which DR said could be strongly linked to Prednisone... I am not convinced i

Hello, I was given Azastin or Avastin for macular edema. I also have retinopathy from diabetes. I was given this shot in my eye in April of this yr. Within 2 days, I had cellulitis in both legs. Horrible pain. Dark red all over from my knees to my

Another thing, can a patient with diabetes type 1 and previously suffered and recovered from Multiple sclerosis ( M-S ) use Spasfon ???

Before I took atenolol i had a perfect glucose numbers after taking it I came down with diabetes. I am 102lbs, 4'11, have always eaten healthy, exercise my whole life. I am 76. I was taken off atenolol after5 years...and NO ONE in my family for ge

Burning sensation, confusion, mental states changes, lethargy, chest pain, pain, communication difficulty.88 years old with astma, high blood pressure, diabetes, prostate enlargement,

Can I take ciprofloxacin with my medicines for diabetes

Can taking of Neuleptil unregularely by father couse a 1st level diabetes for his son?

Dont get discouraged, I am 21 years old and got diagnosed with diabetes when i was 15. I hated it for a little while then i thought well i have to live with it so i better make the best of it. I, just like anyone, wanted to live an ordinary teen life

Good effects on diabetes. weight reduction -rapid and moderate to excessive hair fall after 3 months of use

Hi, I'm 21 years old, recently released from the hospital for possible brain infection (took a variety of antibiotics and anti-virals). I have possible diabetes and I recently developed tinnitus I think, and the possible causes for it is my prolonged

I am 14 and type one diabetic, and i just want it to go away so i can live a normal happy life, i would like to drink to see what its like (typical teen) but i really dont want diabetes , so i don't really care about it, my mum and dad get worried be

DIABETES MELLITUS Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Rank

Status

Study

Recruiting

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Condition:	Multiple Myeloma
Interventions:	Drug: velcade subcutaneous melphalan Prednisone; Drug: velcade cyclophosphamide Prednisone; Drug: velcade Prednisone
Outcome Measures:	Very Good Partial Response, Complete response rate , Partial response rate; Progression free survival; Time to progression; Time to Next Therapy; Overall survival; Time to response; Duration of response; Response rate

Recruiting

The Assessment of Prednisone In Remission Trial (TAPIR) - Patient Centric Approach

Conditions:	Granulomatosis With Polyangiitis; Wegener Granulomatosis; Vasculitis
Interventions:	Drug: 5 mg Prednisone; Drug: 0 mg Prednisone
Outcome Measures:	Prednisone dose increase for disease relapse; Rates of disease flare sub types; Time to event flare; Health related quality of life; Safety Outcomes; Protocol performance

Recruiting

The Assessment of Prednisone In Remission Trial - Centers of Excellence Approach

Condition:	Granulomatosis With Polyangiitis
Interventions:	Drug: Prednisone 5 mg/day; Drug: Prednisone 0 mg/day
Outcome Measures:	Physician decision to increase glucocorticoids for disease relapse.; Time to disease flare.; Safety outcomes.; Protocol performance at VCRC Centers of Excellence.; Health-related quality of life survey; Health-related quality of life surveys

Recruiting

Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis

Condition:	Cellulitis
Interventions:	Drug: Prednisone; Drug: Placebo
Outcome Measures:	Change in VAS for pain - day 1 to 48 hours; Change in erythema size - day 1 to 48 hours; Amount of pain medication - day 1 to 48 hours; Amount of pain medication - day 1 to 7 days; Amount of pain medication - 48 hours to 7 days; Additional Medical Assistance Post-Randomization; Disposition Trend; Adverse Events

Recruiting

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma (CLARION)

Condition:	Multiple Myeloma
Interventions:	Drug: Carfilzomib; Drug: Bortezomib; Drug: Melphalan; Drug: Prednisone
Outcome Measures:	Progression-Free Survival; Overall Survival (OS); Complete Response (CR) rate; Overall Response Rate (ORR); Change from baseline in health-related quality of life (HR-QOL) score

Recruiting

Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy

Condition:	IgA Nephropathy
Interventions:	Drug: Prednisone plus cyclophosphamide; Drug: Prednisone alone
Outcome Measures:	the changes of kidney function; the changes of proteinuria

Recruiting

Efficacy of Prednisone in Patients With Severe Systemic Atheroembolism (Cholesterol Cristal Embolism)

Condition:	Cholesterol Embolism Systemic
Interventions:	Drug: Prednisone; Other: placebo
Outcome Measures:	1-year survival and 1-year renal survival (composite criteria); Number and duration of hospitalization(s); course of renal function; number of cardiovascular events; Prednisone tolerance

Recruiting

Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer

Condition:	Prostate Cancer
Interventions:	Drug: Docetaxel, Reolysin and Prednisone; Drug: Docetaxel and Prednisone
Outcome Measures:	Disease Progression; Effect of Docetaxel and Reolysin on circulating tumour cells; PSA change rate; Objective Response; Overall Survival; Determine patient tolerability and toxicity of Reolysin and Docetaxel in combination; Prognostic/Predictive molecular response

Not yet recruiting

Study of the Prednisone Sparing Effect of Xolair (Omalizumab) in Patients With Prednisone-dependent Asthma With Eosinophilic Bronchitis

Conditions:	Prednisone Dependent Asthma; Eosinophilic Bronchitis
Interventions:	Biological: Omalizumab (Xolair); Drug: Placebo
Outcome Measures:	proportion of patients with exacerbations in each study group from week 0 to week 32.; the magnitude of the reduction in the dose of Prednisone from week 12 to week 32.; change in % sputum eosinophil; Blood eosinophils; Forced Expired Volume in 1 second (FEV1); Ratio of Forced Expired Volume in 1 second to Forced Vital Capacity (FEV1/VC); Provocative concentration causing a 20% drop in FEV1 (PC20); Asthma Control Questionnaire; Fraction of exhaled nitric oxide (FeNO)

Not yet recruiting

Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Conditions:	Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic Leukemia
Interventions:	Biological: blinatumomab; Drug: Prednisone; Drug: vincristine sulfate; Drug: methotrexate; Drug: mercaptopurine; Drug: dasatinib; Other: laboratory biomarker analysis
Outcome Measures:	Overall survival (OS) (Cohort I); Incidence of dose-limiting toxicity, defined as any grade 3-4 non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) (Cohort II); Complete response (CR + CRi) rate (Cohort I); Disease-free survival; Response rates (Cohort II); OS (Cohort II); Incidence of toxicity graded according to National Cancer Institute CTCAE version 4.0; MRD negativity; Time to achieve MRD negativity

Recruiting

Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Condition:	Prostate Cancer Metastatic
Interventions:	Drug: CABAZITAXEL (XRP6258); Drug: DOCETAXEL (XRP6976); Drug: Prednisone
Outcome Measures:	PSA response rate; Circulating tumor cells (CTCs) with response to docetaxel or cabazitaxel treatment; Progression-free survival; PSA progression-free survival rate; Objective response rate; Radiographic progression-free survival (rPFS) rate; Clinical progression-free survival (cPFS); Overall survival

Recruiting

Prednisone Versus Doxycycline in the Treatment of Graves' Orbitopathy

Condition:	Thyroid Associated Opthalmopathies
Interventions:	Drug: Prednisone+placebo of Doxycycline; Drug: Doxycycline+placebo of Prednisone
Outcome Measures:	Overall treatment response; • Health related quality of life questionnaires (GO-QoL); • Safety and tolerability as assessed by adverse events, vital signs; • Quantitative changes of rectus diameter measured by MRI scan; Relapse

Recruiting

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

Condition:	Prostate Neoplasms
Interventions:	Drug: Abiraterone acetate; Drug: Prednisone; Other: Androgen deprivation therapy (ADT); Drug: Abiraterone acetate Placebo; Drug: Prednisone Placebo
Outcome Measures:	Overall Survival (OS); Radiographic progression-free survival (PFS); Time to next skeletal-related event; Time to prostate specific antigen (PSA) progression; Time to next subsequent therapy for prostate cancer; Time to initiation of chemotherapy; Time to Pain Progression

Recruiting

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Conditions:	Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions:	Drug: Alisertib; Drug: Abiraterone acetate; Drug: Prednisone
Outcome Measures:	Phase I: Frequency of dose limiting toxicities of Alisertib, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.1; Phase II: Duration of progression free survival according to the PCWG2 criteria; Change in PSA kinetics

Recruiting

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer

Condition:	Prostate Cancer
Interventions:	Drug: cabazitaxel, Prednisone, custirsen sodium; Drug: cabazitaxel, Prednisone
Outcome Measures:	Survival; Progression-free survival at Day 140

Recruiting

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions:	Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions:	Drug: docetaxel; Drug: pasireotide; Drug: Prednisone
Outcome Measures:	Occurrence of adverse events and the associated grade per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 to identify the maximum tolerated dose (MTD) of pasireotide in combination with docetaxel and Prednisone; All specific types of toxicity as assessed via NCI CTCAE version 4.0; Measurements of tumor using Response Evaluation Criteria In Solid Tumors (RECIST) criteria before and after treatment with the combination of pasireotide in combination with docetaxel; Percentage prostate-specific antigen (PSA) decline noted; Time to Progression (TTP); Overall Survival (OS); Pharmacokinetics (PK) parameters; Measurement of levels of IGF-1, serum chromogranin A (SCA), and neuron specific enolase (NSE), pre-therapy, post-therapy, and the change between time points and association with duration of TTP and OS; Measurements of CTC counts pre-therapy, post-therapy, and the change between time-points and association with duration of TTP and OS

Unknown ^†

Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis

Condition:	Focal Segmental Glomerulosclerosis
Interventions:	Drug: Prednisone, FK506, MMF; Drug: Prednisone
Outcome Measure:	proteinuria,serum protein,Scr,blood routine examination,liver function test,blood glucose and lipid test

Recruiting

Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)

Condition:	Chronic GVHD
Interventions:	Drug: Sirolimus + calcineurin inhibitor + Prednisone; Drug: Sirolimus + Prednisone
Outcome Measures:	Phase II: Proportion of subjects with CR/PR; Phase III: Proportion of subjects with CR; resolution of GVHD manifestations; Phase II: Avg. daily dose % reduction of Prednisone; Phase II: Cumulative incidence of treatment failure; Phase II: Prevalence of active symptomatic chronic GVHD; Phase II: Incidence of discontinuation of all systemic immunosuppressive therapy; Phase II: Overall and cancer progression-free survival; Phase II: Serum biomarkers of chronic GVHD; Phase III: Avg. daily dose % reduction of Prednisone; Phase III: Cumulative incidence of treatment failure; Phase III: Prevalence of active symptomatic chronic GVHD; Phase III: Incidence of discontinuation of all systemic immunosuppressive therapy; Phases III: Overall and cancer progression-free survival; Phase III: Serum biomarkers of chronic GVHD

Unknown ^†

Methotrexate as a Steroid-sparing Agent in Idiopathic Retroperitoneal Fibrosis: a Randomised, Multicenter Trial

Conditions:	Idiopathic Retroperitoneal Fibrosis; Perianeurysmal Retroperitoneal Fibrosis; Chronic Periaortitis
Interventions:	Drug: Methotrexate+Prednisone; Drug: Prednisone
Outcome Measures:	Remission rate by the end of treatment; Reduction in size of the retroperitoneal mass on CT/MRI scans; Rate of post-treatment relapses; Treatment-related toxicity

Recruiting

Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone

Condition:	Prostate Cancer
Interventions:	Drug: Lupron; Drug: Zoladex; Drug: Degarelix; Drug: Abiraterone Acetate; Drug: Prednisone
Outcome Measure:	Prostate Specific Antigen (PSA) Free Survival